Tildrakizumab在多项试验中按患者特征分层的疗效分析
基于2b期和3期试验数据,分析tildrakizumab治疗中重度斑块状银屑病时,患者人口学与疾病特征对疗效的影响。各亚组中tildrakizumab 100/200mg的PASI 75/90应答率均显著高于安慰剂(P<0.0001)。年龄<65岁、体重≤90kg、无银屑病关节炎及未使用生物制剂者应答率数值上更高,但差异无临床意义;性别、种族及传统系统治疗失败次数不影响疗效。
要点
- Tildrakizumab 100/200mg的PASI 75/90应答率在各亚组均显著优于安慰剂(P<0.0001)。
- 年龄<65岁、体重≤90kg、无银屑病关节炎者应答率数值更高,但差异无临床意义。
- 性别、种族及既往传统系统治疗失败次数不影响tildrakizumab疗效。
核心结论
- Tildrakizumab在不同人口学与疾病特征亚组中均显示优于安慰剂的疗效,数值差异无临床意义,适用于广泛中重度斑块状银屑病患者。
研究设计与样本
- 分析P05495(N=355)、reSURFACE 1(N=772)和reSURFACE 2(N=1090)三项试验中接受安慰剂或tildrakizumab 100/200mg的患者数据。
- 按年龄、性别、种族、体重、自报银屑病关节炎、≥1种传统系统治疗失败及既往生物制剂使用定义亚组。
- 比较第12周各亚组内PASI 75和PASI 90应答率,并计算第0和12周绝对PASI。
主要发现
- 各亚组中tildrakizumab 100/200mg的PASI 75和90应答率均显著高于安慰剂(P<0.0001)。
- 年龄<65岁、体重≤90kg、无银屑病关节炎及未使用生物制剂(仅PASI 90)者应答率数值更高。
- 其他亚组间疗效无明确一致差异,绝对PASI在各亚组大致相似。
关键数值与推荐
- 主要疗效指标为第12周PASI 75和PASI 90应答率。
- 亚组包括年龄、性别、种族、体重、银屑病关节炎、传统系统治疗失败史及生物制剂使用史。
临床怎么用
- Tildrakizumab可用于具有不同人口学与疾病特征的中重度斑块状银屑病患者。
- 年龄、体重、银屑病关节炎及既往生物制剂使用所致疗效数值差异较小,不改变临床决策。
局限性
- 亚组间差异为数值性且无临床意义,长期数据可能更有价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tildrakizumab is a high-affinity, anti-interleukin-23p19 monoclonal antibody approved for treatment of moderate-to-severe plaque psoriasis. OBJECTIVES: To evaluate the effects of patient demographic and disease characteristics on tildrakizumab efficacy using phase 2b/3 trial data. METHODS: Data from patients who received placebo, or tildrakizumab 100 or 200 mg, in P05495 [NCT01225731], reSURFACE 1 [NCT01722331] and reSURFACE 2 [NCT01729754] were analysed. Patient subgroups were defined by age, sex, race, weight, self-reported psoriatic arthritis, failure of ≥1 traditional systemic treatment and prior biologic use. Percentage of Psoriasis Area and Severity Index (PASI) 75 and 90 responders at Week 12 were compared across treatment arms in each subgroup. Absolute PASI at Weeks 0 and 12 was also determined for each subgroup. RESULTS: Among patients randomized in P05495 (N = 355), reSURFACE 1 (N = 772) and 2 (N = 1090), percentage of PASI 75 and 90 responders were significantly greater for each tildrakizumab dose vs. placebo (P < 0.0001). PASI 75 and 90 responder percentages were numerically greater in patients <65 years of age, bodyweight ≤90 kg, without psoriatic arthritis and with no prior biologic exposure (only PASI 90), vs. their counterparts in corresponding subgroups. There were no clear or consistent differences in efficacy between the other subgroups. Absolute PASI scores were generally similar across subgroups. CONCLUSIONS: Small numerical differences in tildrakizumab efficacy were observed between subgroups defined by patient age and weight, presence of psoriatic arthritis and prior biologic use. These differences were not clinically meaningful; however, analyses of long-term data may be of value. Tildrakizumab efficacy did not differ with respect to patient sex or race, or number of prior failed conventional systemic treatments. Overall, these results suggest tildrakizumab may be appropriate for treatment of moderate-to-severe plaque psoriasis in patients with a range of demographic and disease characteristics.
引用
- Poulin Y, Ramon M, Rosoph L, et al. Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate-to-severe chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2020. PMID: 31919889. doi:10.1111/jdv.16187
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。